Acompanhe as Notícias da Recifes

EV owners were sent hefty PCNs but say some signs in private car parks fail to warn of fees to park and recharge carDoes refuelling your car class as parking? The answer appears to be yes if it’s an electric vehicle. Guardian Money has been contacted by several readers who were fined after charging their cars away from home.The motorists report being caught out by signs that fail to make clear that charging points are subject to parking tariffs or to store opening times. Also, the

In the UK, these scams have become an epidemic, rising 147% between January and March, compared with the same time last year. Why are they suddenly so common? And what can you do if you’re charged thousands for a quick, easy job?Sarah was alone in her flat with her three-month-old baby when a man put a card machine in her face and demanded she pay £2,209. A few hours earlier Sarah, 30, had been for a walk with her daughter when it dawned on her that she had left her keys at home. She d

Despite spending increase in June, Barclays says most people still pessimistic about economyRelentless sunshine and the World Cup coaxed consumers to spend more on beer and online shopping last month, with purse strings expected to remain loose as England fans gear up for Wednesday’s semi-final.Most people remain pessimistic about the UK economy, according to data from Barclays Bank based on debit and credit card transactions. Continue reading...

Premium cherry-on-the-vine are poised to take top spot in Britain’s £1bn-a-year tomato marketFor a long time the classic round, red tomato has dominated British salads and sandwiches, but its supremacy is coming under threat as sales of rainbow colours and the upmarket rival “cherry on the vine” take off.“Non-red tomatoes” sales are up 21% this year, a growth rate that far exceeds the overall market, according to Paul Faulkner, of Evesham Vale Growers. Continue reading...

Brent crude dips slightly below $78 a barrel; most Asian stock markets bounce backBritain’s second-biggest drugmaker GSK has also taken a hit from recent drug failures.The Californian biotech Alector has said that GSK has ended their neuroscience collaboration covering ​two experimental antibody drugs, after both drug candidates suffered setbacks in clinical trials.The CARDIO-TTRansform trial was designed to examine the role of Wainua, a gene silencer treatment, on top of today’s stand